MedTrace Logo

Ectosomes, New Biomarkers of Tau Pathology?

NCT03381482 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 71

Last updated 2025-08-20

No results posted yet for this study

Summary

In Alzheimer's disease (AD), neurofibrillary degeneration (NFD) is characterized by the intraneuronal aggregation of Tau proteins. The pathology progresses through a hierarchical pathway that may be associated with the intercellular transmission of pathology as demonstrated in our rat models. This transmission implies that Tau is actively secreted and may participate to the first steps of Tau pathology spreading. It is demonstrated in cell lines and animal models (rodents and non-human primates) that Tau is secreted not only in free forms but also in extracellular vesicles. If Tau is found in biological fluids before neuronal death it may represent an early marker of the NFD and will also define therapeutically targets. In this context, the aim is now to transfer this knowledge in humans and to decipher the nature of Tau secreted in plasma and cerebrospinal fluids collected from healthy controls to AD patients, and to decipher if the presence of tau inside vesicles is influenced by the pathology.

Conditions

  • Alzheimer Disease

Interventions

DIAGNOSTIC_TEST

CSF drawing during spinal anaesthesia

4mL of CSF by lumbar puncture

DIAGNOSTIC_TEST

Fasting blood sample

6x5 mL of fasting blood sample

DIAGNOSTIC_TEST

Lumbar puncture

10 mL of CSF by lumbar puncture

Sponsors & Collaborators

  • University Hospital, Lille

    lead OTHER

Principal Investigators

  • Vincent DERAMECOURT, MD,PhD · University Hospital, Lille

Eligibility

Min Age
40 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-12-20
Primary Completion
2022-12-21
Completion
2022-12-23

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03381482 on ClinicalTrials.gov